Sarcoidosis Induced by Adalimumab in Rheumatoid Arthritis.

Tuberculosis and Respiratory Diseases

article

Lee, Seung Ho¹  Kim, Sa Il¹  Song, June Seok¹  Kim, Tae Hyung¹  Sohn, Jang Won¹  Kim, Sang Heon¹  Yoon, Ho Joo¹  Kim, Tae Hwan¹  Shin, Dong Ho¹  Park, Sung Soo¹  Kwak, Hyun Jung¹ 

[1] Department of Internal Medicine, Hanyang University College of Medicine

关键词: Tumor Necrosis Factor-alpha;    Antibodies;    Monoclonal;    Humanized;    Sarcoidosis;    Arthritis;    Rheumatoid;   

DOI  :  10.4046/trd.2011.71.6.464

学科分类：医学（综合）

来源: The Korean Academy of Tuberculosis and Respiratory Diseases

【 摘 要 】

Adalimumab is a full human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha). This has recently been shown to be effective in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis, and other conditions. Sacoidosis is known to be the target for adalimumab but we describe a patient who has developed sarcoidosis with lung involvement during adalimumab therapy for RA. A 48-year-old woman, who was treated with adalimumab for 5 months, was admitted because of chronic cough and both hilar lymphadenopathy on chest radiography. Chest computed tomography revealed the enlargement of multiple lymph nodes in the right supraclavicular, subcarinal, both hilar and right axillary area. She was diagnosed with sarcoidosis based on the biopsy of supraclavicular lymph node, skin and lung through video-associated thoracoscopic surgery, which was non-caseating epitheloid cell granuloma and excluded from a similar disease. She was treated for sarcoidosis with prednisolone and methotrexate instead of adalimumab.

【 授权许可】

CC BY-NC